MX2024003455A - Sistemas de represores de casx dise?ados por ingenieria genetica. - Google Patents
Sistemas de represores de casx dise?ados por ingenieria genetica.Info
- Publication number
- MX2024003455A MX2024003455A MX2024003455A MX2024003455A MX2024003455A MX 2024003455 A MX2024003455 A MX 2024003455A MX 2024003455 A MX2024003455 A MX 2024003455A MX 2024003455 A MX2024003455 A MX 2024003455A MX 2024003455 A MX2024003455 A MX 2024003455A
- Authority
- MX
- Mexico
- Prior art keywords
- casx
- engineered
- repressor systems
- systems
- repressor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163246543P | 2021-09-21 | 2021-09-21 | |
| US202263321517P | 2022-03-18 | 2022-03-18 | |
| PCT/US2022/076774 WO2023049742A2 (en) | 2021-09-21 | 2022-09-21 | Engineered casx repressor systems |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003455A true MX2024003455A (es) | 2024-04-03 |
Family
ID=83902730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003455A MX2024003455A (es) | 2021-09-21 | 2022-09-21 | Sistemas de represores de casx dise?ados por ingenieria genetica. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20240392271A1 (https=) |
| EP (1) | EP4405479A2 (https=) |
| JP (1) | JP2024534523A (https=) |
| KR (1) | KR20240095525A (https=) |
| AU (1) | AU2022349627A1 (https=) |
| CA (1) | CA3231909A1 (https=) |
| CL (1) | CL2024000835A1 (https=) |
| GB (1) | GB2625500B (https=) |
| IL (1) | IL311610A (https=) |
| MX (1) | MX2024003455A (https=) |
| PE (1) | PE20240728A1 (https=) |
| TW (1) | TW202320864A (https=) |
| WO (1) | WO2023049742A2 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12021553076A1 (en) | 2019-06-07 | 2023-08-14 | Scribe Therapeutics Inc | Engineered casx systems |
| AU2021392719B2 (en) | 2020-12-03 | 2025-08-14 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
| WO2022261150A2 (en) | 2021-06-09 | 2022-12-15 | Scribe Therapeutics Inc. | Particle delivery systems |
| JP2024534523A (ja) | 2021-09-21 | 2024-09-20 | スクライブ・セラピューティクス・インコーポレイテッド | 操作されたｃａｓｘリプレッサー系 |
| EP4419685A1 (en) * | 2021-10-20 | 2024-08-28 | University of Rochester | Compositions and methods for treating myelin deficiency by rejuvenating glial progenitor cells |
| US20250388885A1 (en) * | 2022-03-11 | 2025-12-25 | Epicrispr Biotechnologies, Inc. | Compositions, systems, and methods for treating familial hypercholesterolemia by targeting pcsk9 |
| CN119421951A (zh) * | 2022-05-31 | 2025-02-11 | 瑞泽恩制药公司 | 用于c9orf72重复序列扩增疾病的crispr干扰疗法 |
| WO2023235818A2 (en) * | 2022-06-02 | 2023-12-07 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
| WO2023235888A2 (en) | 2022-06-03 | 2023-12-07 | Scribe Therapeutics Inc. | COMPOSITIONS AND METHODS FOR CpG DEPLETION |
| WO2023240027A1 (en) | 2022-06-07 | 2023-12-14 | Scribe Therapeutics Inc. | Particle delivery systems |
| WO2023240076A1 (en) | 2022-06-07 | 2023-12-14 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
| WO2023240074A1 (en) | 2022-06-07 | 2023-12-14 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
| US20250361525A1 (en) | 2022-06-08 | 2025-11-27 | Scribe Therapeutics Inc. | Aav vectors for gene editing |
| WO2023250509A1 (en) * | 2022-06-23 | 2023-12-28 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of b2m expression |
| IL317874A (en) | 2022-06-24 | 2025-02-01 | Tune Therapeutics Inc | Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression |
| TW202444906A (zh) | 2023-03-29 | 2024-11-16 | 美商斯奎柏治療公司 | 用於靶向pcsk9之組合物及方法 |
| WO2024206565A1 (en) | 2023-03-29 | 2024-10-03 | Scribe Therapeutics Inc. | Repressor fusion protein systems |
| WO2024223911A1 (en) * | 2023-04-28 | 2024-10-31 | Ziccum Ab | Nanoparticle formulations |
| WO2024229020A2 (en) * | 2023-05-01 | 2024-11-07 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of pcsk9 expression |
| WO2025072293A1 (en) * | 2023-09-27 | 2025-04-03 | Scribe Therapeutics Inc. | Optimized mrnas encoding casx proteins |
| CN117143257B (zh) * | 2023-10-31 | 2024-02-09 | 深圳市帝迈生物技术有限公司 | Trim28-krab-znf10二元复合物、制备方法及用于前列腺癌筛查的试剂盒 |
| WO2025101979A1 (en) * | 2023-11-08 | 2025-05-15 | Nchroma Bio, Inc. | Compositions and methods for epigenetic regulation of genes for treatment of non-alcoholic steatohepatitis or metabolic dysfunction-associated steatohepatitis |
| CN117887718B (zh) * | 2024-03-14 | 2025-02-28 | 青岛宝迈得生物科技有限公司 | 一种mettl6基因抑制剂及其应用 |
| CN120966794A (zh) * | 2024-05-16 | 2025-11-18 | 君福生物科技(广州)有限公司 | 用于表观遗传编辑的融合蛋白及其应用 |
| CN118931878B (zh) * | 2024-10-14 | 2025-02-07 | 内蒙古大学 | 一种基于CRISPR/dCas9的表观遗传基因编辑系统及其应用 |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| ATE219660T1 (de) | 1994-09-30 | 2002-07-15 | Inex Pharmaceuticals Corp | Mittel zum einbringen polyanionischer materialien in zellen |
| ATE544776T1 (de) | 1994-12-29 | 2012-02-15 | Massachusetts Inst Technology | Chimäre dna-bindeproteine |
| US5695937A (en) | 1995-09-12 | 1997-12-09 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
| US7368551B2 (en) | 1998-06-25 | 2008-05-06 | The General Hospital Corporation | De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| EP1276859B1 (en) | 2000-04-28 | 2007-02-07 | Sangamo Biosciences Inc. | Targeted modification of chromatin structure |
| US6919204B2 (en) | 2000-09-29 | 2005-07-19 | Sangamo Biosciences, Inc. | Modulation of gene expression using localization domains |
| WO2002057294A2 (en) | 2001-01-22 | 2002-07-25 | Sangamo Biosciences, Inc. | Zinc finger proteins for dna binding and gene regulation in plants |
| CA2461290C (en) | 2001-09-24 | 2014-11-25 | Sangamo Biosciences, Inc. | Modulation of stem cells using zinc finger proteins |
| WO2003072788A1 (en) | 2002-02-21 | 2003-09-04 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for reversibly controlling expression of target genes in cells |
| WO2005028630A2 (en) | 2003-09-19 | 2005-03-31 | Sangamo Biosciences, Inc. | Engineered zinc finger proteins for regulation of gene expression |
| US20070192880A1 (en) | 2003-10-03 | 2007-08-16 | University Of Rochester | Horming response element binding transregulators |
| US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
| JP5042863B2 (ja) | 2005-02-14 | 2012-10-03 | サーナ・セラピューティクス・インコーポレイテッド | 生物学的に活性な分子をデリバリーするための脂質ナノ粒子系組成物および方法 |
| WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| AU2009238175C1 (en) | 2008-04-15 | 2023-11-30 | Arbutus Biopharma Corporation | Novel lipid formulations for nucleic acid delivery |
| US20120207744A1 (en) | 2009-03-19 | 2012-08-16 | Mendlein John D | Reprogramming compositions and methods of using the same |
| US20110071208A1 (en) | 2009-06-05 | 2011-03-24 | Protiva Biotherapeutics, Inc. | Lipid encapsulated dicer-substrate interfering rna |
| ES2613498T3 (es) | 2009-07-01 | 2017-05-24 | Protiva Biotherapeutics Inc. | Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos |
| US8450107B1 (en) | 2011-11-30 | 2013-05-28 | The Broad Institute Inc. | Nucleotide-specific recognition sequences for designer TAL effectors |
| EP3241902B1 (en) * | 2012-05-25 | 2018-02-28 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| WO2014093718A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| US20140271550A1 (en) | 2013-03-14 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses |
| EP3004370B1 (en) | 2013-06-05 | 2024-08-21 | Duke University | Rna-guided gene editing and gene regulation |
| AU2014346559B2 (en) | 2013-11-07 | 2020-07-09 | Editas Medicine,Inc. | CRISPR-related methods and compositions with governing gRNAs |
| WO2015138870A2 (en) | 2014-03-13 | 2015-09-17 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeted epigenetic modification |
| SMT202200502T1 (it) | 2014-06-25 | 2023-01-13 | Acuitas Therapeutics Inc | Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici |
| GB201418965D0 (https=) | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
| US11219634B2 (en) | 2015-01-21 | 2022-01-11 | Genevant Sciences Gmbh | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
| US11674144B2 (en) | 2015-04-16 | 2023-06-13 | California Institute Of Technology | Fractional regulation of transcription |
| TWI813532B (zh) | 2015-06-18 | 2023-09-01 | 美商博得學院股份有限公司 | 降低脱靶效應的ｃｒｉｓｐｒ酶突變 |
| LT3313829T (lt) | 2015-06-29 | 2024-08-12 | Acuitas Therapeutics Inc. | Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui |
| WO2017068077A1 (en) | 2015-10-20 | 2017-04-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods and products for genetic engineering |
| IL307179A (en) | 2015-10-28 | 2023-11-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| WO2017083722A1 (en) | 2015-11-11 | 2017-05-18 | Greenberg Kenneth P | Crispr compositions and methods of using the same for gene therapy |
| US20190127713A1 (en) | 2016-04-13 | 2019-05-02 | Duke University | Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use |
| WO2017212008A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
| WO2017212007A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Cationic carriers for nucleic acid delivery |
| US10017760B2 (en) | 2016-06-24 | 2018-07-10 | Inscripta, Inc. | Methods for generating barcoded combinatorial libraries |
| JP7308143B2 (ja) | 2016-08-19 | 2023-07-13 | ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ | Ｄｎａメチル化の編集方法 |
| JP7682604B2 (ja) | 2016-09-07 | 2025-05-26 | フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド | 遺伝子発現をモジュレートするための方法および組成物 |
| CA3038960A1 (en) * | 2016-09-30 | 2018-04-05 | The Regents Of The University Of California | Rna-guided nucleic acid modifying enzymes and methods of use thereof |
| WO2018111944A1 (en) | 2016-12-12 | 2018-06-21 | Whitehead Institute For Biomedical Research | Regulation of transcription through ctcf loop anchors |
| US11591621B2 (en) | 2017-02-07 | 2023-02-28 | Modalis Therapeutics Corporation | Method of treating diseases associated with elevated KRAS expression using CRISPR-GNDM system |
| WO2018195555A1 (en) | 2017-04-21 | 2018-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Crispr/cas 9-mediated integration of polynucleotides by sequential homologous recombination of aav donor vectors |
| US20230340471A1 (en) | 2017-04-23 | 2023-10-26 | Ospedale San Raffaele S.R.L. | Permanent Epigenetic Gene Silencing |
| US11439692B2 (en) | 2017-05-17 | 2022-09-13 | Modalis Therapeutics Corporation | Method of treating diseases associated with MYD88 pathways using CRISPR-GNDM system |
| US11072782B2 (en) | 2017-07-24 | 2021-07-27 | Albert-Ludwigs-Universitaet Freiburg | Construct for epigenetic modification and its use in the silencing of genes |
| US20190233805A1 (en) | 2017-10-04 | 2019-08-01 | The Regents Of The University Of California | Targetable proteins for epigenetic modification and methods for use thereof |
| US11629342B2 (en) | 2017-10-17 | 2023-04-18 | President And Fellows Of Harvard College | Cas9-based transcription modulation systems |
| CA3079727A1 (en) | 2017-10-24 | 2019-05-02 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of rare diseases |
| US20210047653A1 (en) | 2018-01-30 | 2021-02-18 | The University Of Memphis Research Foundation | Compositions and methods for regulating a biological process |
| JP7555822B2 (ja) | 2018-04-19 | 2024-09-25 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | ゲノム編集のための組成物および方法 |
| WO2020023529A1 (en) | 2018-07-24 | 2020-01-30 | The Regents Of The University Of California | Rna-guided nucleic acid modifying enzymes and methods of use thereof |
| US12275964B2 (en) | 2018-08-22 | 2025-04-15 | The Regents Of The University Of California | Variant type V CRISPR/Cas effector polypeptides and methods of use thereof |
| CN113286620A (zh) | 2018-08-24 | 2021-08-20 | 莱兰斯坦福初级大学评议会 | 用于多核苷酸空间组织的系统和方法 |
| CA3115158A1 (en) | 2018-10-02 | 2020-04-09 | Sangamo Therapeutics, Inc. | Engineered genetic modulators |
| MX2021012836A (es) | 2019-04-23 | 2021-12-10 | Sangamo Therapeutics Inc | Moduladores de la expresion del gen del marco de lectura abierto 72 del cromosoma 9 y usos de los mismos. |
| CA3138576A1 (en) | 2019-05-16 | 2020-11-19 | Trustees Of Boston University | Regulated synthetic gene expression systems |
| CA3135271A1 (en) | 2019-05-28 | 2020-12-03 | Astellas Pharma Inc. | Method for treating muscular dystrophy by targeting dmpk gene |
| WO2020247883A2 (en) | 2019-06-07 | 2020-12-10 | Scribe Therapeutics Inc. | Deep mutational evolution of biomolecules |
| PH12021553076A1 (en) | 2019-06-07 | 2023-08-14 | Scribe Therapeutics Inc | Engineered casx systems |
| EP4010004A4 (en) | 2019-08-07 | 2023-09-13 | Altius Institute For Biomedical Sciences | Compositions and methods for modulation of gene expression |
| AU2020352931A1 (en) | 2019-09-23 | 2022-03-31 | Flagship Pioneering Innovations V, Inc. | Modulating genomic complexes |
| US20220343485A1 (en) | 2019-10-02 | 2022-10-27 | Nippon Telegraph And Telephone Corporation | Video quality estimation apparatus, video quality estimation method and program |
| US20230036273A1 (en) | 2019-11-27 | 2023-02-02 | The General Hospital Corporation | System and method for activating gene expression |
| AU2020398658A1 (en) * | 2019-12-06 | 2022-07-07 | Scribe Therapeutics Inc. | Particle delivery systems |
| CA3176046A1 (en) | 2020-05-04 | 2021-11-11 | Michael C. BASSIK | Compositions, systems, and methods for the generation, identification, and characterization of effector domains for activating and silencing gene expression |
| IL298434A (en) | 2020-06-02 | 2023-01-01 | Univ California | Gene editing compositions and methods |
| AU2021325586A1 (en) | 2020-08-14 | 2023-03-23 | The Governing Council Of The University Of Toronto | KRAB fusion repressors and methods and compositions for repressing gene expression |
| CA3192654A1 (en) | 2020-09-01 | 2022-03-10 | The Board Of Trustees Of The Leland Stanford Junior Unversity | Synthetic miniature crispr-cas (casmini) system for eukaryotic genome engineering |
| WO2022047624A1 (en) | 2020-09-01 | 2022-03-10 | Huigene Therapeutics Co., Ltd | Small cas proteins and uses thereof |
| US20240026352A1 (en) | 2020-11-13 | 2024-01-25 | Duke University | Targeted gene regulation of human immune cells with crispr-cas systems |
| AR124143A1 (es) | 2020-11-25 | 2023-02-15 | Astellas Pharma Inc | Método para tratar la distrofia muscular mediante el direccionamiento al gen dmpk |
| WO2022119957A1 (en) | 2020-12-02 | 2022-06-09 | The Regents Of The University Of California | Crispr-cas effector polypeptides and methods of use thereof |
| AU2021392719B2 (en) | 2020-12-03 | 2025-08-14 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
| EP4259791A1 (en) | 2020-12-09 | 2023-10-18 | Scribe Therapeutics Inc. | Aav vectors for gene editing |
| CA3202977A1 (en) | 2020-12-22 | 2022-06-30 | Chroma Medicine, Inc. | Compositions and methods for epigenetic editing |
| KR20230152689A (ko) | 2021-02-01 | 2023-11-03 | 엡실렌 바이오 에스.알.엘. | 유전자 침묵 |
| WO2022261150A2 (en) | 2021-06-09 | 2022-12-15 | Scribe Therapeutics Inc. | Particle delivery systems |
| WO2023004338A2 (en) | 2021-07-20 | 2023-01-26 | Epicrispr Biotechnologies, Inc. | Systems and methods for regulating target genes |
| WO2023023553A2 (en) | 2021-08-17 | 2023-02-23 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions, systems, and methods for activating and silencing gene expression |
| MX2024003007A (es) | 2021-09-08 | 2024-03-25 | Metagenomi Inc | Sistemas crispr de clase ii, tipo v. |
| JP2024534523A (ja) | 2021-09-21 | 2024-09-20 | スクライブ・セラピューティクス・インコーポレイテッド | 操作されたｃａｓｘリプレッサー系 |
| IL311611A (en) | 2021-09-23 | 2024-05-01 | Scribe Therapeutics Inc | Self-inactivating gene-editing vectors |
| WO2023055893A1 (en) | 2021-09-30 | 2023-04-06 | Peter Biotherapeutics, Inc. | Gene regulation |
| EP4437092A1 (en) | 2021-11-26 | 2024-10-02 | Epigenic Therapeutics Inc. | Method of modulating pcsk9 and uses thereof |
| CN116497002A (zh) | 2022-01-19 | 2023-07-28 | 中国科学院动物研究所 | 工程化的CasX核酸酶、效应蛋白及其用途 |
| TW202346588A (zh) | 2022-03-04 | 2023-12-01 | 大陸商益杰立科（上海）生物科技有限公司 | 基因組編輯的組成物和方法 |
| US20250388885A1 (en) | 2022-03-11 | 2025-12-25 | Epicrispr Biotechnologies, Inc. | Compositions, systems, and methods for treating familial hypercholesterolemia by targeting pcsk9 |
| EP4493700A2 (en) | 2022-03-17 | 2025-01-22 | The Board of Trustees of the Leland Stanford Junior University | Compositions and methods for modulating alpha-synuclein expression |
| EP4519293A1 (en) | 2022-05-01 | 2025-03-12 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of pcsk9 expression |
| WO2023235818A2 (en) | 2022-06-02 | 2023-12-07 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
| WO2023240076A1 (en) | 2022-06-07 | 2023-12-14 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
| CN114921439B (zh) | 2022-06-16 | 2024-04-26 | 尧唐(上海)生物科技有限公司 | CRISPR-Cas效应子蛋白、其基因编辑系统及应用 |
| CA3259638A1 (en) | 2022-06-23 | 2023-12-28 | Nchroma Bio, Inc. | EPIGENETIC COMPOSITIONS AND EDITING PROCESSES |
| WO2023250148A1 (en) | 2022-06-23 | 2023-12-28 | Chroma Medicine, Inc. | Compositions and methods for epigenetic editing |
| CA3260110A1 (en) | 2022-06-24 | 2023-12-28 | European Molecular Biology Laboratory | MODULAR TOOL BASED ON CRISPR FOR THE SPECIFIC INTRODUCTION OF EPIGENETIC MODIFICATIONS ON TARGET LOCI |
| IL317874A (en) | 2022-06-24 | 2025-02-01 | Tune Therapeutics Inc | Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression |
| WO2024032681A1 (zh) | 2022-08-11 | 2024-02-15 | 益杰立科(上海)生物科技有限公司 | 一种表观编辑靶点的方法及用途 |
| KR20250128349A (ko) | 2022-12-23 | 2025-08-27 | 에피제닉 테라퓨틱스 피티이 리미티드 | 융합체 및 이의 용도 |
| TW202444910A (zh) | 2023-03-29 | 2024-11-16 | 美商斯奎柏治療公司 | 編碼casx之信使rna |
| TW202444906A (zh) | 2023-03-29 | 2024-11-16 | 美商斯奎柏治療公司 | 用於靶向pcsk9之組合物及方法 |
| WO2024206565A1 (en) | 2023-03-29 | 2024-10-03 | Scribe Therapeutics Inc. | Repressor fusion protein systems |
-
2022
- 2022-09-21 JP JP2024517501A patent/JP2024534523A/ja active Pending
- 2022-09-21 EP EP22793333.0A patent/EP4405479A2/en active Pending
- 2022-09-21 PE PE2024000522A patent/PE20240728A1/es unknown
- 2022-09-21 TW TW111135799A patent/TW202320864A/zh unknown
- 2022-09-21 GB GB2405484.3A patent/GB2625500B/en active Active
- 2022-09-21 CA CA3231909A patent/CA3231909A1/en active Pending
- 2022-09-21 WO PCT/US2022/076774 patent/WO2023049742A2/en not_active Ceased
- 2022-09-21 MX MX2024003455A patent/MX2024003455A/es unknown
- 2022-09-21 US US18/693,062 patent/US20240392271A1/en active Pending
- 2022-09-21 KR KR1020247012262A patent/KR20240095525A/ko active Pending
- 2022-09-21 IL IL311610A patent/IL311610A/en unknown
- 2022-09-21 AU AU2022349627A patent/AU2022349627A1/en active Pending
-
2024
- 2024-03-21 US US18/612,882 patent/US12553037B2/en active Active
- 2024-03-21 CL CL2024000835A patent/CL2024000835A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2024000835A1 (es) | 2024-10-04 |
| KR20240095525A (ko) | 2024-06-25 |
| GB2625500B (en) | 2026-04-01 |
| GB2625500A (en) | 2024-06-19 |
| WO2023049742A3 (en) | 2023-05-04 |
| TW202320864A (zh) | 2023-06-01 |
| US12553037B2 (en) | 2026-02-17 |
| WO2023049742A2 (en) | 2023-03-30 |
| IL311610A (en) | 2024-05-01 |
| EP4405479A2 (en) | 2024-07-31 |
| AU2022349627A1 (en) | 2024-03-21 |
| US20240392271A1 (en) | 2024-11-28 |
| PE20240728A1 (es) | 2024-04-15 |
| GB202405484D0 (en) | 2024-06-05 |
| JP2024534523A (ja) | 2024-09-20 |
| US20240254466A1 (en) | 2024-08-01 |
| CA3231909A1 (en) | 2023-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024003455A (es) | Sistemas de represores de casx dise?ados por ingenieria genetica. | |
| PH12021551114A1 (en) | Crispr-cas12j enzyme and system | |
| MX2019003674A (es) | Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas. | |
| BR112021012665A2 (pt) | Polipeptídeos úteis para edição de genes e métodos de uso | |
| MX2022001849A (es) | Nucleasas guiadas por acido ribonucleico (arn) y sus fragmentos activos y variantes y metodos de uso. | |
| BR112020024863A2 (pt) | Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso | |
| MX2023008931A (es) | Complejos de transposoma ligados a superficie de complejo. | |
| WO2019139645A3 (en) | High efficiency base editors comprising gam | |
| CL2023001593A1 (es) | Composiciones y métodos para dirigirse específicamente a bcl11a | |
| BR112019006388A2 (pt) | enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas | |
| MX2017003847A (es) | Proteinas biespecificas activables por proteasas. | |
| MX2020003339A (es) | Arn guía de cpf1 modificado. | |
| CO7151523A2 (es) | Método y composiciones para la modificación de adn objetivo dirigida por arn y para la modulación de la transcripción dirigida por arn | |
| DE602006011574D1 (de) | Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung | |
| MX2019007248A (es) | Enzimas de polimerizacion para reacciones de secuenciacion. | |
| EA202190454A1 (ru) | Новый crispr-ассоциированный белок и его применение | |
| MX2022004657A (es) | Secuenciacion de tejidos intactos a escala clinica e industrial. | |
| AR070693A1 (es) | Plantas que tienen rasgos aumentados relacionados con el rendimiento y un metodo para obtenerlas a partir de la expresion del polipeptido de nitrato 2 (nrt2) | |
| MX2021013907A (es) | Matriz y método para la detección de información espacial de ácidos nucleicos. | |
| PE20211660A1 (es) | Neoantigenos prostaticos y sus usos | |
| BR112023003526A2 (pt) | Proteínas de fusão de coronavírus imunogênicos e métodos relacionados | |
| MX2017010359A (es) | Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc). | |
| MX2025011494A (es) | Sistemas de proteinas de fusion represoras | |
| MX2025000833A (es) | Anticuerpos que se unen a peptidil arginina deiminasa 4 (pad4) humana y usos de los mismos | |
| ECSP17075380A (es) | Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos |